The tragedy of the commons is a well-known economic model that describes what happens when individuals act solely according to their own self-interest in a manner contrary to the common good. 1 This problem is not unheard of in our profession, 2 with the tragedy of the medical commons having applicability both to patients and physicians acting solely in their own self-interest. An important lesson is that two responses can occur as the result of the tragedy of the commons: government intervention/regulation and privatization. These two responses are not mutually exclusive.
Many of us are fortunate to have access to innovations that can markedly improve our patients' lives, and many use these innovations prudently, mindful of our duty to be good stewards of the resources we administer. A few will see newer applications for innovative interventions and will explore those newer applications wisely, in keeping with the good of their patients and profession. As we all know, unfortunately, this is not the conduct of all of our colleagues.
For example, with balloon sinuplasty, an important and valuable technology, self-interest has driven some of our colleagues to push the application of this newly established procedure to achieve economic or financial goals not related to prudent patient care. This problem may occur with any innovative therapy so novel that the limits of its use remain to be understood and defined. As we have seen with balloon sinuplasty, the response of the media, government, and private insurers to this behavior can be devastatingly disproportionate and risk hobbling the appropriate and beneficial use of the new technology.
Through the work of dedicated clinicians and researchers, and with the support of industry, our specialty has another new innovative therapy, balloon eustachian tube (ET) dilatation, or balloon eustachian tuboplasty. Foresight would demand that our specialty make the effort to mitigate the risk of a similar tragedy of the medical commons. The current, published, peer-reviewed literature is the best guide on its application, and could be promulgated as preliminary clinical criteria, to be revised and updated as clinical experience and outcomes dictate.
Based on this literature, reasonable criteria may be laid out along the following lines: Patients likely to be appropriate candidates for eustachian tuboplasty are those with a medical history of unilateral or bilateral GUEST EDITORIAL persistent otitis media with effusion or significant nonadherent tympanic membrane atelectasis.
3 Examination in all patients should document tympanic membrane morphology and motility on otomicroscopy. Nasal cavity, ET orifice, and nasopharynx should be evaluated by office endoscopy. Audiometry and tympanometry should be obtained for all patients unless contraindicated medically. Audiograms may be normal in patients with a ventilation tube or small perforation.
Conservative measures, including but not limited to intranasal steroids, treatment of laryngopharyngeal reflux, and a trial of tympanostomy tubes, should be considered before eustachian tuboplasty. Those who after conservative measures cannot successfully insufflate with a gentle Valsalva maneuver, preferably after Politzer insufflation, may be considered appropriate candidates for balloon eustachian tuboplasty.
John Stuart Mill, a champion of liberty, warned of the dangers when a minority's self-interest disproportionately influences how a resource is used. 4 Fortunately, we have the ideas of such luminaries as the late Nobel-Prize-winning economist Elinor Ostrom on how to sustainably manage "common-pool resources" through community stewardship. 5 For the sake of our patients and colleagues, we have an obligation and the ability to avoid the tragedy of the commons with balloon eustachian tuboplasty and other new technologies.
